Moderna, Inc.

MRNA · Nasdaq · ·

比較

$223.22-3.5%11月13日終値

2026年9月30日までの数値（2026年11月6日提出の10-Qより）

1W: -12.2%
1M: -5.6%
3M: +253%

Moderna, Inc.（MRNA）株——良い事業でしょうか？ — InspectStocks

Moderna, Inc.

MRNA · Nasdaq · ·

比較

$223.22-3.5%11月13日終値

2026年9月30日までの数値（2026年11月6日提出の10-Qより）

1W: -12.2%
1M: -5.6%
3M: +253%

Just reported

Q3 2026 results

From Moderna's results release of 2026年11月6日; its quarterly report has since been filed.

Revenue
Actual
$1.31B
+29% y/y
Guided
—
No guide given
EPS, GAAP
Actual
$0.38
Guided
—
No guide given
Operating income, GAAP
Actual
$130M
Guided
—
No guide given

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Moderna is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The themes it is part of

キュレーション
Biotech
InspectStocks 編集 · 19 companies
Drug developers with approved medicines, built mainly on biologic and genetic science.
株価、1 年
+26.8%
売上、1 年
+12.9%
+13
A 8B 4C 5D 1F 1

Highest-graded in Biotechnology

Graded A or B and worth $2B or more: A first, then the largest.

All 352 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

どうやって稼いでいるか

COVID-19 vaccine sales, including Spikevax and mNEXSPIKE93%
Payments for manufacturing capacity4%
Government and other grants1%
Collaboration revenue1%
Licensing and royalties1%
RSV vaccine sales, including mRESVIA0%

売上構成比はyear ended 2025-12-31の推計であり、提出された報告書の数字ではありません。

競合

何を売っているか6

Spikevax
A COVID-19 vaccine updated to target circulating virus variants.
mNEXSPIKE
A COVID-19 vaccine that uses a lower mRNA dose than Spikevax and focuses the immune response on key parts of the virus.
mRESVIA
An RSV vaccine for older adults and certain adults at increased risk of severe RSV illness.

さらに3件を表示

mFLUSIVA
An influenza vaccine approved in the United States and Canada for adults aged 50 and older; commercial sales began in September 2026.
mCOMBRIAX
A vaccine combining protection against influenza and COVID-19, authorized in Europe and Canada for adults aged 50 and older; it had not been commercialized by September 30, 2026.
Intismeran autogene (mRNA-4157)
An investigational personalized cancer treatment designed around mutations in an individual patient's tumor; it is being developed with Merck alongside pembrolizumab.

誰が買っているか4

Wholesalers and distributors, which are the main route for sales in the United States.
Retail pharmacies, health care providers and government entities, which also buy vaccines in the United States.
Governments and international organizations that purchase vaccines.
Governments in the United Kingdom, Canada and Australia, which have multi-year commitments to purchase mRNA products.

何に支えられ、何に崩されうるか

事業が頼っているもの

1COVID-19 vaccine sales made up 93.1% of revenue in 2025, tying revenue closely to demand for those vaccines.
2Vaccine sales are seasonal and depend on public health recommendations, changes in circulating viruses and whether people choose to get vaccinated.
3Some materials and manufacturing processes rely on single-source suppliers, and the company also uses outside manufacturers and suppliers.
4Intismeran autogene is being developed with Merck, with development costs and potential profits or losses generally shared equally.
5Vaccine products can require cold storage and careful shipping.

うまくいかなくなる可能性

1Demand for seasonal vaccines can change with public health recommendations, virus circulation, customer orders and willingness to vaccinate; these changes can affect sales.
2Clinical trials and regulatory reviews may delay or prevent approval of new vaccines and treatments; the influenza vaccine mRNA-1010 had faced a regulatory filing setback before its amended application was accepted for review.
3Manufacturing or supply problems, including supplier interruptions, product-release issues or failures to maintain required shipping and storage conditions, could delay or limit product supply.

財務諸表をすべて見る →

Moderna, Inc.について

Moderna makes vaccines using messenger RNA (mRNA), which gives cells instructions to make a protein that can help prevent or treat disease. It also develops mRNA-based treatments, including a personalized cancer treatment being developed with Merck and treatments for rare inherited diseases. As of September 30, 2026, it had five approved products, though its flu-plus-COVID vaccine had not yet been commercialized.

本社: Cambridge, Massachusetts
設立: 2010
上場市場: Nasdaq
決算期: December 31

Moderna, Inc. 自身が米国証券取引委員会（SEC）に提出した書類にもとづきます。数字は報告されたままで、1 株当たりの履歴は今日の株数基準に修正済みです。これは事業の説明です——投資助言ではなく、売買を勧めるものでもありません。

Just reported

Q3 2026 results

From Moderna's results release of 2026年11月6日; its quarterly report has since been filed.

Revenue
Actual
$1.31B
+29% y/y
Guided
—
No guide given
EPS, GAAP
Actual
$0.38
Guided
—
No guide given
Operating income, GAAP
Actual
$130M
Guided
—
No guide given